SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

VIR

Vir Biotechnology Inc.
NASDAQHealth Care

Latest close: 9.96 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Oct 14, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Oct 8, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  3. Oct 1, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record76610 flagged findings
Reported transactions (Form 4)80since May 29, 2024 · and 15 other holdings
Corporate events (8-K)30since May 20, 2022

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

What the company does

biotech company

Source: Wikidata (CC0 1.0) · copied on Sep 3, 2026 · may not reflect recent changes.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-07regulatory investigationrecentOpen filing ↗
    “…Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions…”
  • 2026-05-07Department of Justice inquiryrecentOpen filing ↗
    “…been issued. Failure to comply with such requirements, when and if applicable, could subject us to a number of actions by applicable…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 766)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Oct 14, 268-K ↗Current report · Sold unregistered shares new
  • Oct 8, 268-K ↗Current report · Other events
  • Oct 6, 26Form 3 ↗Insider transaction
  • Oct 1, 268-K ↗Current report · A senior executive left or was appointed
  • Notice of proposed sale · 5 Form 144 filingsshow all 5hide
  • Aug 12, 26Form 4 ↗Insider transaction
  • Aug 7, 26SCHEDULE 13G ↗Passive stake · STATE STREET CORPORATION · 5.9% · event on Jun 30, 26
  • Aug 5, 2610-Q ↗Quarterly report
  • Aug 5, 268-K ↗Current report · Results
  • Jul 31, 26SCHEDULE 13G/A ↗Passive stake · Vanguard Portfolio Management · 6.8% · event on Jun 30, 26 · amendment
  • Jul 24, 268-K ↗Current report · A senior executive left or was appointed
  • Jun 29, 26Form 144 ↗Notice of proposed sale
  • Jun 10, 26Form 4 ↗Insider transaction
  • Jun 10, 26Form 3 ↗Insider transaction
  • Jun 10, 268-K ↗Current report · A senior executive left or was appointed
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Notice of proposed sale · 2 Form 144 filingsshow all 2hide
  • Insider transaction · 2 Form 4 filingsshow all 2hide

766 filings on record, the oldest from Jul 25, 19.

Listing the 25 most recent filings of the 766 on record.

8-Ks, explained

Stress2Structure32Governance19
  • Oct 14, 26StructureSold unregistered shares+2 more in the same filing8-K 3.02 ↗
  • Governance6 senior executive changes2026show all 6hide
    • Oct 1, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Jul 24, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Jun 10, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • May 28, 26GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Apr 10, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Mar 4, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Feb 26, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Feb 23, 26StructureSold unregistered shares+4 more in the same filing8-K 3.02 ↗
  • Dec 16, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Jan 30, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Sep 10, 24StructureCompleted an acquisition or disposal+3 more in the same filing8-K 2.01 ↗
  • Aug 1, 24StressRestructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
  • Aug 1, 24StructureEntered a material agreement8-K 1.01 ↗
  • Apr 18, 24GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Feb 22, 24StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Feb 20, 24GovernanceA senior executive left or was appointed8-K 5.02 ↗

10 older filings not shown · The record reaches back to Oct 16, 19.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • Dec 13, 23StressRestructuring plan with committed costs8-K 2.05 ↗

The full record holds 2 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • Robert Nelsen8.5%Feb 27, 26SCHEDULE 13D/A ↗8 co-filers on this document — the figure is the largest single stake, not their sum.

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • BlackRock, Inc.10.8%Mar 31, 25SCHEDULE 13G/A ↗
  • Vanguard Portfolio Management6.8%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing
  • SB Investment Advisers (UK) Limited6.5%Mar 31, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • STATE STREET CORPORATION5.9%Jun 30, 26SCHEDULE 13G ↗

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Sep 17, O'Byrne Jason filed notice of intent to sell up to $213K. That is about 0.01% of shares outstanding.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

No sale of theirs is on record yet in Form 4; the 90-day window is still open.

View notice (Form 144) ↗+5 more recent notices

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Jun 1, 26Sell$4KBrent SabatiniSVP, Chief Accounting Officer↗
  • Jun 1, 26Sell$30KJanet Napolitano↗
  • May 1, 26Sell$221KVICKI L SATO↗
  • Apr 6, 26Sell$664KBacker Marianne DePresident and CEO↗
  • Apr 1, 26Sell$200KVICKI L SATO↗
  • Mar 23, 26Sell$70KBrent SabatiniSVP, Chief Accounting Officer↗
  • Mar 2, 26Sell$207KVICKI L SATO↗
  • Mar 2, 26Sell$2KVICKI L SATO↗
  • Feb 25, 26Sell$135KVerneuil Vanina deEVP, General Counsel, Corp Sec↗
  • Feb 25, 26Sell$19KMark EisnerEVP and Chief Medical Officer↗
  • Feb 24, 26Sell$141KBacker Marianne DeChief Executive Officer↗
  • Feb 24, 26Sell$30KVerneuil Vanina deEVP, General Counsel, Corp Sec↗

There are 11 more transactions in this stretch.

Stock compensation, tax and giftsshow the 17 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Aug 11, 26Otheramount n/aROBERT J MORE↗
  • Aug 11, 26Otheramount n/aROBERT J MORE↗
  • Jun 9, 26Compensationamount n/aTimothy Coughlin↗
  • May 27, 26Compensationamount n/aJeffrey S. Hatfield↗
  • May 27, 26Compensationamount n/aNORBERT W BISCHOFBERGER↗
  • May 27, 26Compensationamount n/aRamy Farid↗
  • May 27, 26Compensationamount n/aROBERT J MORE↗
  • May 27, 26Compensationamount n/aJanet Napolitano↗
  • Apr 29, 26Otheramount n/aBacker Marianne DePresident and CEO↗
  • Mar 20, 26Otheramount n/aJason O'ByrneEVP & Chief Financial Officer↗
  • Mar 20, 26Otheramount n/aJason O'ByrneEVP & Chief Financial Officer↗
  • Feb 24, 26Compensation$63KVICKI L SATO↗
  • Feb 22, 26Compensationamount n/aBacker Marianne DeChief Executive Officer↗
  • Feb 22, 26Compensationamount n/aVerneuil Vanina deEVP, General Counsel, Corp Sec↗
  • Feb 22, 26Compensationamount n/aMark EisnerEVP and Chief Medical Officer↗
  • Feb 22, 26Compensationamount n/aJason O'ByrneEVP & Chief Financial Officer↗
  • Feb 22, 26Compensationamount n/aBrent SabatiniSVP, Chief Accounting Officer↗

The full record holds 285 transactions and goes back to Dec 21, 22.

Its sector and its market

Vir Biotechnology Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Vir Biotechnology Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Vir Biotechnology Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
766 documents on file, from Jul 25, 2019 to Oct 14, 2026.
Company description
Wikidata, read on Sep 3, 2026.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.

Vir Biotechnology Inc. (VIR): stock price history, insider trades and SEC filings — HornScout